



Press Release

For Immediate Release

AilsynBio and Dong-E-E-Jiao Sign Project Cooperation Agreement

Empowering Traditional Medicine with AI to Open a New Chapter in the Health Industry

(Hong Kong, 10 April 2026) - AilsynBio, an AI-driven drug discovery company, held a Project Cooperation Agreement Signing Ceremony today at the Hong Kong Science Park, announcing a comprehensive project cooperation agreement with **Dong-E-E-Jiao Co., Ltd. (000423.SZ)**. This partnership marks a profound cross-sector integration of Artificial Intelligence (AI) and traditional medicine, aiming to empower biopharmaceutical innovation through technological means.

The ceremony brought together influential leaders and experts from industry, academia, and research sectors, including senior representatives from **China Resources Pharmaceutical Group, Hong Kong Science and Technology Parks Corporation (HKSTP)**, and **The University of Hong Kong (HKU)**, to witness this significant milestone.

Derek Chim, Head of Startup Ecosystem and Development of HKSTP, said: “This cooperation reflects exactly what Incu-Bio was built to achieve — nurturing startups that partner with global leaders like Dong-E-E-Jiao. It’s proof that the ecosystem works and that our approach delivers real results. It also demonstrates HKSTP’s growing focus on biotech innovation and AI, which now spans the entire healthcare value chain. We congratulate both teams on this achievement and look forward to seeing more collaborations like this emerge from Hong Kong’s vibrant innovation community.”

Dr Bo Chen, Chief Scientist of China Resources Pharmaceutical, noted: “This collaboration with Dong-E-E-Jiao and AilsynBio is an important practice for China Resources Pharmaceutical in promoting the modernization of Traditional Chinese Medicine (TCM). It represents a deep integration of industry, academia, and research in the field of ‘AI + TCM’ between Mainland China and Hong Kong. We look forward to integrating scientific research and industrial resources from both regions to solve the challenges of TCM’s mechanisms of action and provide an innovative path for TCM to evolve from empirical medicine to evidence-based medicine.”

Liang Zheng, Vice President of Dong-E-E-Jiao, stated: “As a core strategic product for Dong-E-E-Jiao, deepening the scientific value of Compound E-Jiao Syrup is crucial for our brand upgrade. This cooperation will strengthen the scientific foundation of our products in the field of women’s health, helping Dong-E-E-Jiao accelerate into a new stage of ‘reshaping TCM wisdom through technological innovation.’”

Pierre Wang, Managing Director of HKU Versitech Limited, stated: “HKU Versitech is honored to witness this project cooperation between HKU spin-off AilsynBio Ltd. and China Resources Pharmaceutical Group Limited subsidiary Dong-E E-Jiao, a partnership that exemplifies the successful translation of world-class academic research into high-impact industrial applications. This cooperation will continue to serve as a vital catalyst for the company’s rapid international growth and its mission to scale cutting-edge biotechnology globally.”



Looking ahead, the two parties will focus on three key collaborative directions:

- **Advancing AI-driven innovation:** Leveraging AilsynBio's AI drug discovery platform to accelerate biopharmaceutical R&D processes.
- **Launching specialized research:** Engaging in in-depth cooperation on the "Premature Ovarian Insufficiency (POI)" research project.
- **Promoting cross-border fusion:** Exploring the integration of biotechnology, AI, and traditional medicine to jointly create a new paradigm for the health industry.

During the ceremony, **AilsynBio** and **Dong-E-E-Jiao** signed the agreement on behalf of their respective organizations. The signing was witnessed by **Dr Bo Chen**, Chief Scientist of China Resources Pharmaceutical; **Eric Or**, Chief Ecosystem Development Officer of HKSTP; and **Pierre Wang**, Managing Director of HKU Versitech.

AilsynBio stated that this cooperation is not only a combination of technologies but also a strategic layout for future healthcare innovation. By leveraging AI technology, the partnership aims to inject technological vitality into traditional medicine for the benefit of more patients.

###

About China Resources Pharmaceutical

China Resources Pharmaceutical Group Limited (Stock code: 03320.HK) is a comprehensive pharmaceutical company in China, with operations covering industrial manufacturing and commercial distribution of pharmaceutical products, healthcare products, and medical devices. The company manufactures 840 products, with a portfolio including chemical drugs, traditional Chinese medicine, biologics, health supplements, and medical devices, covering a wide range of therapeutic areas. It owns well-known brands such as "999", "Dong-E E-Jiao", and "Jiangzhong". In 2024, China Resources Pharmaceutical achieved turnover of RMB 257.67 billion, with a business network covering 28 provinces across China and over 270,000 customers.

About Dong-E E-Jiao

Dong-E E-Jiao Co., Ltd. (000423.SZ) is an enterprise engaged in the production and operation of E-Jiao and related products. As a subsidiary of state-owned China Resources Group, it is primarily involved in the R&D, production, and sales of E-Jiao and related Chinese patent medicines, health foods, and food products. The company, formerly known as Shandong Dong-E E-Jiao Factory, was established in 1952, listed on the Shenzhen Stock Exchange in 1996, and joined China Resources Group in 2005. The company houses the National Gelatin Traditional Chinese Medicine Engineering Technology Research Center and a postdoctoral research workstation. It is recognized as a National High-Tech Enterprise, a National Innovative Enterprise, a National Intangible Cultural Heritage Enterprise, and a National Traditional Chinese Medicine Culture Publicity and Education Base. Its products are sold not only in the domestic market but also in over 10 countries and regions, including Southeast Asia, Europe, and the Americas.



About AilsynBio

AilsynBio is a biotechnology startup headquartered in Hong Kong, focusing on AI-driven drug design and development, with the goal of shortening R&D cycles and driving breakthroughs in life sciences. AilsynBio has developed a drug R&D technology system that integrates artificial intelligence with physicochemical principles, including proprietary PyTorch models, the L3BA physics engine, and the AI Agent technology, to streamline the drug molecular design process. The team focuses initially on macrocyclic drug development, addressing an unmet market need. It has also built an automated DTN system to achieve a closed loop throughout the drug R&D process, continuously optimizing molecular screening results through AI learning. The team has established partnerships with seven pharmaceutical companies across different regions, validating its algorithms and systems in the market.

About Hong Kong Science and Technology Parks Corporation

Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 12 unicorns, more than 16,000 research professionals and over 2,400 technology companies from 25 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.

Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimaged.

Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.

Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong.

More information about HKSTP is available at www.hkstp.org.

Media Contact:

Hong Kong Science and Technology Parks Corporation

July Wu

Tel: +852 6533 8165

Email: july.wu@hkstp.org

AilsynBio Limited

Dr Bella Zheng

Tel: +852 5935 2394

Email: u3006786@connect.hku.hk